文献速递血栓与止血贫血与红细胞疾病

COVID-19的分类与预后评估中的血液学特征及危险因素:一项回顾性队列研究

Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study.
PubMed 文献 · Lancet Haematol · 2020-07-10

这项回顾性队列研究纳入武汉协和医院三个院区2020年1月23日至2月23日收治的380例COVID-19患者,比较中型、重型与危重型患者的血液学特征,发现血小板减少、淋巴细胞和嗜酸性粒细胞降低、凝血指标升高与疾病严重程度相关;多因素分析显示中性粒细胞与淋巴细胞比值≥9.13、血小板减少、凝血酶原时间延长和D-二聚体升高与死亡相关。

要点

  • 危重型患者血小板减少发生率49%,显著高于重型14%和中型6%(p<0.0001)。
  • 死亡与中性粒细胞与淋巴细胞比值≥9.13、血小板减少、凝血酶原时间>16秒、D-二聚体>2 mg/L相关。
  • 脓毒症诱导凝血病评分可用于危重型患者的早期评估和管理。

核心结论

  • 快速血液检查包括血小板计数、凝血酶原时间、D-二聚体和中性粒细胞与淋巴细胞比值可帮助临床医生评估COVID-19患者的严重程度和预后。
  • 脓毒症诱导凝血病评分系统可用于危重型患者的早期评估和管理。

研究设计与样本

  • 回顾性队列研究,纳入武汉协和医院三个指定院区2020年1月23日至2月23日收治的380例COVID-19患者。
  • 疾病严重程度按中国国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第七版)》定义分为中型、重型和危重型。
  • 从电子病历中提取人口学、临床、实验室、治疗和结局数据,采用线性混合模型分析动态血液学和凝血参数,并应用脓毒症诱导凝血病和国际血栓与止血学会显性弥散性血管内凝血评分系统进行凝血病筛查。

主要发现

  • 危重型患者血小板减少(血小板计数<100×10^9/L)发生率为42/86(49%),显著高于重型20/145(14%)和中型9/149(6%)(p<0.0001)。
  • 危重型患者淋巴细胞和嗜酸性粒细胞数量显著低于重型和中型患者(p<0.0001),凝血酶原时间、D-二聚体和纤维蛋白降解产物随疾病严重程度增加而显著升高(p<0.0001)。
  • 多因素分析显示,死亡与中性粒细胞与淋巴细胞比值≥9.13(OR 5.39,95%CI 1.70-17.13,p=0.0042)、血小板减少(血小板计数<100×10^9/L;OR 8.33,95%CI 2.56-27.15,p=0.00045)、凝血酶原时间延长(>16秒;OR 4.94,95%CI 1.50-16.25,p=0.0094)和D-二聚体升高(>2 mg/L;OR 4.41,95%CI 1.06-18.30,p=0.041)相关。
  • 死亡患者中血栓和出血事件常见,为19/55(35%)。
  • 脓毒症诱导凝血病和国际血栓与止血学会显性弥散性血管内凝血评分(在12例存活者和8例死亡者中评估)在死亡患者中随时间升高,脓毒症诱导凝血病的发生通常早于显性弥散性血管内凝血。

关键数值与推荐

  • 血小板减少定义为血小板计数<100×10^9/L。
  • 中性粒细胞与淋巴细胞比值阈值为≥9.13(OR 5.39,95%CI 1.70-17.13,p=0.0042)。
  • 凝血酶原时间阈值为>16秒(OR 4.94,95%CI 1.50-16.25,p=0.0094)。
  • D-二聚体阈值为>2 mg/L(OR 4.41,95%CI 1.06-18.30,p=0.041)。

临床怎么用

  • 快速血液检查包括血小板计数、凝血酶原时间、D-二聚体和中性粒细胞与淋巴细胞比值可帮助临床医生评估COVID-19患者的严重程度和预后。
  • 脓毒症诱导凝血病评分系统可用于危重型患者的早期评估和管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important features of the disease. We aimed to explore the haematological characteristics and related risk factors in patients with COVID-19. METHODS: This retrospective cohort study included patients with COVID-19 admitted to three designated sites of Wuhan Union Hospital (Wuhan, China). Demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records and compared between patients with moderate, severe, and critical disease (defined according to the diagnosis and treatment protocol for novel coronavirus pneumonia, trial version 7, published by the National Health Commission of China). We assessed the risk factors associated with critical illness and poor prognosis. Dynamic haematological and coagulation parameters were investigated with a linear mixed model, and coagulopathy screening with sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scoring systems was applied. FINDINGS: Of 466 patients admitted to hospital from Jan 23 to Feb 23, 2020, 380 patients with COVID-19 were included in our study. The incidence of thrombocytopenia (platelet count <100 × 109 cells per L) in patients with critical disease (42 [49%] of 86) was significantly higher than in those with severe (20 [14%] of 145) or moderate (nine [6%] of 149) disease (p<0·0001). The numbers of lymphocytes and eosinophils were significantly lower in patients with critical disease than those with severe or moderate disease (p<0·0001), and prothrombin time, D-dimer, and fibrin degradation products significantly increased with increasing disease severity (p<0·0001). In multivariate analyses, death was associated with increased neutrophil to lymphocyte ratio (≥9·13; odds ratio [OR] 5·39 [95% CI 1·70-17·13], p=0·0042), thrombocytopenia (platelet count <100 × 109 per L; OR 8·33 [2·56-27·15], p=0·00045), prolonged prothrombin time (>16 s; OR 4·94 [1·50-16·25], p=0·0094), and increased D-dimer (>2 mg/L; OR 4·41 [1·06-18·30], p=0·041). Thrombotic and haemorrhagic events were common complications in patients who died (19 [35%] of 55). Sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scores (assessed in 12 patients who survived and eight patients who died) increased over time in patients who died. The onset of sepsis-induced coagulopathy was typically before overt disseminated intravascular coagulation. INTERPRETATION: Rapid blood tests, including platelet count, prothrombin time, D-dimer, and neutrophil to lymphocyte ratio can help clinicians to assess severity and prognosis of patients with COVID-19. The sepsis-induced coagulopathy scoring system can be used for early assessment and management of patients with critical disease. FUNDING: National Key Research and Development Program of China.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020. PMID: 32659214. doi:10.1016/S2352-3026(20)30217-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。